The estimated Net Worth of Global Strategic Fund Ii L.... is at least $98.8 Million dollars as of 1 July 2020. Global L owns over 116,467 units of Akero Therapeutics Inc stock worth over $77,719,602 and over the last 5 years Global sold AKRO stock worth over $21,086,357.
Global has made over 13 trades of the Akero Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Global sold 116,467 units of AKRO stock worth $4,006,465 on 1 July 2020.
The largest trade Global's ever made was selling 494,000 units of Akero Therapeutics Inc stock on 13 January 2020 worth over $9,993,620. On average, Global trades about 90,100 units every 29 days since 2019. As of 1 July 2020 Global still owns at least 3,033,552 units of Akero Therapeutics Inc stock.
You can see the complete history of Global L stock trades at the bottom of the page.
Over the last 5 years, insiders at Akero Therapeutics Inc have traded over $146,260,704 worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth $104,250,550 . The most active insiders traders include Group, Llc Green Jeremy Red..., Trust Blue Horizon Enterpri..., and G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,642,344. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth $133,600.
akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
Akero Therapeutics Inc executives and other stock owners filed with the SEC include: